Otsuka Holdings will pay ICU Medical (Nasdaq: ICUI) an upfront payment of $200 million as part of a joint venture to enter the U.S. IV products market, which has been facing hurricane-related shortages this fall. The partnership — which involves  ICU Medical providing commercial services for Otsuka’s Otsuka Pharmaceutical Factory (OPF) subsidiary — also includes…

Vitrian announced that it closed a $50 million investment into AmplifyBio and its manufacturing enablement center (AMEC) in Ohio. AmplifyBio, a leading advanced therapy CRO and CDMO, offers a full range of drug development and manufacturing services. The investment, which could scale to $65 million, marks a step toward a larger commitment to support biomanufacturing…

Baxter recently stopped selling IV products in China as it continues its efforts to address hurricane-related supply shortages in the U.S. In a statement shared with Pharmaceutical Processing World, the Deerfield, Illinois–based company said: “After careful consideration, and given the numerous alternative IV solution suppliers that exist in the Chinese market, Baxter has suspended commercial…

Terumo Blood and Cell Technologies (BCT) announced that it plans to expand its offerings to Latin America. The company plans to help bring automated manufacturing to cell and gene therapy companies in Brazil, Colombia and Mexico. With a focus on automation, it makes products that collect, process and separate blood and cells. The company also…

MilliporeSigma, Merck KGaA’s U.S. and Canada Life Science business, announced a $76 million expansion of its ADC manufacturing capabilities and capacity. The company is expanding the capacity at its Bioconjugation Center of Excellence facility in St. Louis. This investment triples existing capacity and enhances the company’s contract development and manufacturing organization (CDMO) offering. MilliporeSigma said…

Samsung Biologics announced a contract manufacturing deal with an unnamed Asia-based pharmaceutical company worth $1.24 billion. According to a news release, it’s the largest contract signed by a single client. Production will take place at Samsung Biologics’ biomanufacturing site in Songdo, South Korea. The contract runs through December 2037. With this agreement, the company’s accumulated…

PharmaLogic announced today that it opened a new radiopharmaceutical production and research facility in Salt Lake City. The new state-of-the-art facility marks “a major step forward” in the CDMO’s mission to deliver diagnostic and therapeutic radiopharmaceuticals to patients across North America, according to a news release. PharmaLogic said it chose to establish the facility in…

Cellular Origins and Fresenius Kabi announced today that they signed a development agreement over cell and gene therapies (CGTs). The agreement leverages both companies’ expertise in CGTs. They aim to digitally and physically integrate Fresenius Kabi’s suite of cell therapy processing technologies with Cellular Origins’ CGT robotic manufacturing platform, Constellation. With this integration, the companies…

MilliporeSigma, the U.S. and Canadian Life Science unit of Merck KGaA (Darmstadt, Germany) announced today that it opened a new $317 million (€290) biosafety testing facility in Rockville, Maryland. The 23,000-square-meter facility houses biosafety testing, analytical development and cell banking manufacturing services. It consolidates labs currently spread across four buildings into one single facility. MilliporeSigma…

Thermo Fisher Scientific announced today that it introduced more sustainable packaging for 125,000 Invitrogen antibodies. The Waltham, Massachusetts-based company said the transition from cold-chain packaging to ambient temperature shipping from distribution center to customer reduces package material mass and improves the customer experience. This comes as part of the company’s global sustainability efforts. According to…